Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Giles

Showing results (51-60 of 130) with videos related to

Pageof 13
Sort By:
Clinical and Laboratory Haematology|September 27, 2006
Simplified sensitive method for the detection of B-cell clonality in lymphoid malignanciesI Jilani, M Keating, A Day, et al.
Blood|February 27, 2001
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blastsB D Smolich, H A Yuen, K A West, et al.
British Journal of Haematology|October 1, 1994
Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivoA P Jewell, C P Worman, P M Lydyard, et al.
British Journal of Haematology|February 1, 1994
Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLLA P Jewell, K L Yong, C P Worman, et al.
British Journal of Haematology|April 1, 1990
Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical responseW C de Mel, A V Hoffbrand, F J Giles, et al.
Leukemia|May 1, 1992
Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cellsA P Jewell, K L Yong, C P Worman, et al.
Leukemia|August 22, 2003
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromesS Yazji, F J Giles, A-M Tsimberidou, et al.
Leukemia|April 4, 2008
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismH Zhang, D Trachootham, W Lu, et al.
American Journal of Hematology|February 19, 2000
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocolF J Giles, N R Wickham, B L Rapoport, et al.
Leukemia & Lymphoma|January 28, 1999
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S M O'Brien, et al.
Pageof 13

Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
Clinical and Laboratory Haematology|September 27, 2006
Simplified sensitive method for the detection of B-cell clonality in lymphoid malignanciesI Jilani, M Keating, A Day, et al.
Blood|February 27, 2001
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blastsB D Smolich, H A Yuen, K A West, et al.
British Journal of Haematology|October 1, 1994
Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivoA P Jewell, C P Worman, P M Lydyard, et al.
British Journal of Haematology|February 1, 1994
Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLLA P Jewell, K L Yong, C P Worman, et al.
British Journal of Haematology|April 1, 1990
Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical responseW C de Mel, A V Hoffbrand, F J Giles, et al.
Leukemia|May 1, 1992
Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cellsA P Jewell, K L Yong, C P Worman, et al.
Leukemia|August 22, 2003
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromesS Yazji, F J Giles, A-M Tsimberidou, et al.
Leukemia|April 4, 2008
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismH Zhang, D Trachootham, W Lu, et al.
American Journal of Hematology|February 19, 2000
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocolF J Giles, N R Wickham, B L Rapoport, et al.
Leukemia & Lymphoma|January 28, 1999
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S M O'Brien, et al.
Pageof 13